Fujimoto N - Search Results

1

Premature Mortality Due to Malignancies of the Kidney and Bladder in Japan, 1980-2010.

Pham TM, Kubo T, Fujino Y, Fujimoto N, Tomisaki I, Minato A, Matsuda S. Pham TM, et al. Among authors: fujimoto n. J Epidemiol. 2019 Dec 5;29(12):464-470. doi: 10.2188/jea.JE20180140. Epub 2018 Nov 24. J Epidemiol. 2019. PMID: 30473546 Free PMC article.

2

Industry-based retrospective cohort study of the risk of prostate cancer among rotating-shift workers.

Kubo T, Oyama I, Nakamura T, Kunimoto M, Kadowaki K, Otomo H, Fujino Y, Fujimoto N, Matsumoto T, Matsuda S. Kubo T, et al. Among authors: fujimoto n. Int J Urol. 2011 Mar;18(3):206-11. doi: 10.1111/j.1442-2042.2010.02714.x. Int J Urol. 2011. PMID: 21332815

3

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer.

Fujimoto N, Kubo T, Shinsaka H, Matsumoto M, Shimajiri S, Matsumoto T. Fujimoto N, et al. BMC Urol. 2011 May 14;11:7. doi: 10.1186/1471-2490-11-7. BMC Urol. 2011. PMID: 21569574 Free PMC article. Clinical Trial.

4

Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer.

Fujimoto N, Shiota M, Kubo T, Matsumoto T. Fujimoto N, et al. Expert Rev Clin Pharmacol. 2010 Nov;3(6):785-95. doi: 10.1586/ecp.10.119. Expert Rev Clin Pharmacol. 2010. PMID: 22111781

5

Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer.

Minato A, Fujimoto N, Kubo T, Harada S, Akasaka S, Matsumoto T. Minato A, et al. Among authors: fujimoto n. Med Oncol. 2012 Dec;29(4):2895-900. doi: 10.1007/s12032-012-0178-z. Epub 2012 Feb 10. Med Oncol. 2012. PMID: 22323054

6

SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.

Bui HT, Fujimoto N, Kubo T, Inatomi H, Matsumoto T. Bui HT, et al. Among authors: fujimoto n. Cancer Invest. 2014 Jul;32(6):256-61. doi: 10.3109/07357907.2014.907421. Epub 2014 Apr 24. Cancer Invest. 2014. PMID: 24762081

7

Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer.

Fujimoto N, Kubo T, Tomisaki I. Fujimoto N, et al. Clin Genitourin Cancer. 2015 Aug;13(4):359-363. doi: 10.1016/j.clgc.2015.02.013. Epub 2015 Mar 5. Clin Genitourin Cancer. 2015. PMID: 25907231

8

An Effective Case for Chyluria by Retroperitoneoscopic Lymphatic Disconnection.

Tomisaki I, Hamasuna R, Fujimoto N. Tomisaki I, et al. Among authors: fujimoto n. J Endourol Case Rep. 2016 Apr 1;2(1):78-80. doi: 10.1089/cren.2016.0044. eCollection 2016. J Endourol Case Rep. 2016. PMID: 27579424 Free PMC article.

9

Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer.

Fujimoto N, Shiota M, Tomisaki I, Minato A. Fujimoto N, et al. Clin Genitourin Cancer. 2017 Jun;15(3):337-342. doi: 10.1016/j.clgc.2017.01.006. Epub 2017 Jan 18. Clin Genitourin Cancer. 2017. PMID: 28188049 Review.

10

Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.

Minato A, Fujimoto N, Kubo T. Minato A, et al. Among authors: fujimoto n. Clin Genitourin Cancer. 2017 Dec;15(6):e1063-e1067. doi: 10.1016/j.clgc.2017.07.008. Epub 2017 Jul 22. Clin Genitourin Cancer. 2017. PMID: 28803791

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,182 results

Search Page

Filters